UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Inclusion Criteria

• Capable of giving signed informed consent
• Age ≥18 years
• ECOG performance status ≤2.
• Phase Ia (dose-escalation part only): Subjects with relapsed and/or refractory B-cell malignancies (CLL/SLL, DLBCL, FL, MCL, WM or MZL) who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion.
• Phase Ib (dose-expansion only): Subjects with relapsed and/or refractory B-cell malignancies who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion, and fit into one of the following groups: CLL/SLL or DLBCL or MCL or FL, WM, MZL
• All subjects must have evaluable or measurable disease based on the appropriate tumor type criteria
• Adequate organ and bone marrow function Key

Exclusion Criteria

• For subjects with lymphoma:
• Systemic antineoplastic therapy or any experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, before the first dose of study treatment.
• Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
• Unconjugated monoclonal antibody therapies <6 weeks before the first dose of study treatment.
• Subjects that have undergone autologous stem cell rescue within 100 days prior to the first dose of study treatment.
• Subjects that have undergone allogeneic stem cell transplant within 6 months prior to the first dose of study treatment.
• Subjects with active graft-versus-host disease (GVHD) or on anti-GVHD treatment or prophylaxis.
• History of chimeric antigen receptor T cell (CAR-T) therapy within 100 days prior to start of study drug.
• Any immunotherapy within 4 weeks of first dose of study drug.
• The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drug is <5 times the t1/2 of the previously administered agent(s).
• Previously exposed to BTK degradation therapy
• Malignant disease, other than that being treated in this study.
• Radiotherapy within 2 weeks of the first dose of study treatment
• Known hypersensitivity to BTK degraders or any of the ingredients.
• Impaired cardiac function or clinically significant cardiac disease
• Subjects with history of severe bleeding disorders and known/suspected other autoimmune disease
• Major surgery within 4 weeks of the first dose of study treatment